Glucose Transporter Type 1 (GLUT1), encoded by the SLC2A1 gene, is a facilitative transmembrane protein involved in basal glucose uptake and cellular energy homeostasis. It is widely expressed in human tissues, with physiologically elevated levels in erythrocytes and endothelial cells of the blood–brain barrier. In oncology research, GLUT1 expression has been frequently reported to be increased in malignant cells, consistent with enhanced glycolytic activity and hypoxia-associated signaling pathways. These characteristics support its investigation in immunohistochemistry (IHC), pulmonary pathology, and cancer metabolism research.

Biological Significance of GLUT1 (SLC2A1)

GLUT1 contributes to cellular energy balance through constitutive glucose transport:

• Mediates basal glucose uptake required for ATP production under physiological and hypoxic conditions.
• Increased expression has been reported in lung carcinomas, including in association with hypoxia-related pathways such as HIF-1α signaling.
• Elevated SLC2A1 expression has been associated in some studies with enhanced glycolysis and tumor progression in non-small cell lung cancer.
• Differential expression between normal and neoplastic pulmonary tissues has been described, supporting its evaluation as a tumor-associated metabolic marker.

Diagnostic Utility of GLUT1 (SLC2A1) in Pulmonary Pathology

GLUT1 IHC is evaluated as part of a panel-based diagnostic approach:

• Typically demonstrates membranous staining in malignant epithelial cells, including lung adenocarcinoma and squamous cell carcinoma.
• Reported to be expressed in malignant pleural effusions of pulmonary origin, with generally lower expression in benign/reactive mesothelial cells, although overlap may occur.
• May contribute to the distinction between malignant mesothelioma and reactive mesothelium when interpreted alongside complementary markers.
• Expression may vary depending on tumor subtype, specimen type, and assay conditions, requiring appropriate validation and contextual interpretation.

Key Features of Anti-GLUT1 (SLC2A1) CE/IVD Antibodies

• Intended for detection of GLUT1 protein in formalin-fixed, paraffin-embedded (FFPE) tissues.
• Compatible with established clinical IHC workflows.
• Supports evaluation of glucose transporter expression in pulmonary pathology specimens.
• For use as part of a multiparametric diagnostic strategy.
• Performance characteristics should be established by each laboratory in accordance with applicable CE/IVD requirements.